Analysts See $0.98 EPS for Innospec Inc. (IOSP)

April 22, 2018 - By Nellie Frank

Innospec Inc. (NASDAQ:IOSP) Logo

Analysts expect Innospec Inc. (NASDAQ:IOSP) to report $0.98 EPS on May, 8 after the close.They anticipate $0.02 EPS change or 2.00 % from last quarter’s $1 EPS. IOSP’s profit would be $24.30 million giving it 18.81 P/E if the $0.98 EPS is correct. After having $1.47 EPS previously, Innospec Inc.’s analysts see -33.33 % EPS growth. The stock increased 1.37% or $1 during the last trading session, reaching $73.75. About 107,516 shares traded. Innospec Inc. (NASDAQ:IOSP) has risen 10.33% since April 22, 2017 and is uptrending. It has underperformed by 1.22% the S&P500.

Innospec Inc. (NASDAQ:IOSP) Ratings Coverage

Among 3 analysts covering Innospec (NASDAQ:IOSP), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Innospec had 3 analyst reports since November 9, 2017 according to SRatingsIntel. Monness Crespi & Hardt downgraded the shares of IOSP in report on Thursday, November 9 to “Neutral” rating. The stock of Innospec Inc. (NASDAQ:IOSP) earned “Overweight” rating by KeyBanc Capital Markets on Thursday, November 9. Johnson Rice upgraded the stock to “Accumulate” rating in Tuesday, November 14 report.

Innospec Inc. develops, manufactures, blends, markets, and supplies fuel additives, oilfield chemicals, personal care products, and other specialty chemicals to gas and oil exploration and production, oil refinery, fuel users, personal care formulation, home care, agrochemical and mining formulation, and other chemical and industrial companies worldwide. The company has market cap of $1.83 billion. It operates through four divisions: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives. It has a 29.27 P/E ratio. The Fuel Specialties segment offers a range of specialty chemical products used as additives in various fuels.

Innospec Inc. (NASDAQ:IOSP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.